HealthInsights

Oral diseases , which impact around 3.5 billion people worldwide, are one of the major global health burdens while being completely preventable. Gum (periodontal) disease and dental caries, sometimes referred to as cavities or tooth decay, are the two conditions that have the biggest negative effects on oral health and account for the majority of the burden of oral illness. Significant risk factors for the emergence of oral disorders include consuming sugar-rich foods and snacks, smoking, drinking alcohol, and ingesting some hazardous foods and beverages. Expanding urbanization, filthy conditions, changing lifestyles, and restricted access to oral health care services all have an impact on oral health disorders. The WHO estimates that 520 million children and over 2 billion people worldwide suffer from primary tooth decay in 2019. More than 40% of individuals reported having oral pain in 2018 as well, and by the age of 34, more than 80% of people will have had at least one cavity. Unt...

Alpha-1 Antitrypsin Deficiency Overview In the twenty-first century, public health has made a substantial contribution to the knowledge and management of diseases. An early diagnosis can still play a role in managing and treating serious illnesses. One of these rare genetic disorders, alpha-1 antitrypsin deficiency (AATD) , has seen advancements in terms of awareness and factors considered during treatment. Therapies for alpha-1 antitrypsin deficiency today mostly involves alpha-1 antitrypsin augmentation treatment. This is the procedure for extracting and injecting normal AAT from blood plasma. The current alpha-1 antitrypsin augmentation treatments include ARALAST (Takeda), GLASSIA (Kamada/Takeda), PROLASTIN/PROLASTIN-C (Grifols), ZEMAIRA (CSL Behring), and ALFALASTIN. The market for their therapy is worth billions of dollars, despite the fact that these drugs for alpha-1 antitrypsin insufficiency are pricey and do not have widespread approval. Grifols is the main rival in the US an...

What is Chronic Pain? A pain that lasts longer than three months is referred to as chronic pain. It might develop gradually and repeat sporadically, lasting longer than the typical healing period and negatively affecting the person's wellbeing. After injured tissue heals, pain is meant to go away until the underlying cause is addressed. Chronic pain is the primary cause of adult disability in the United States. 50 million Americans today suffer from chronic pain. The most frequent causes of chronic pain include lower back problems, arthritis, cancer, RSDS, repetitive stress disorders, shingles, headaches, and fibromyalgia. Others include neurological conditions like diabetic neuropathy and phantom limb experience. Sports injuries are one of the most frequent reasons for persistent pain in adults in their twenties. Chronic pain increases societal costs each year. Musings on the chronic pain treatment  The prevalence of Chronic pain is quite common in cancer patients, but it has a...

What is Amyotrophic Lateral Sclerosis?  A disorder of the neurological system that impairs physical function and weakens muscles is called Amyotrophic Lateral Sclerosis (ALS). The amyotrophic lateral sclerosis treatment environment is strict and includes multidisciplinary care, such as physical therapy, speech therapy, food counselling, heat or whirlpool therapy, and other procedures. Amyotrophic lateral sclerosis can be treated with the following drugs: RILUZOLE, RADICAVA, TIGLUTIK, EXSERVAN, and RELYVRIO. ALS-related disease progression cannot currently be slowed down or stopped by any effective treatment. The cornerstones of ALS treatment are palliative care and symptom management. RADICAVA, the first Amyotrophic Lateral Sclerosis medication in decades since Riluzole approval with an eye-popping price tag RADICAVA (edaravone), the second drug used to treat ALS patients, decreases the loss of physical function in ALS patients. Despite being used to treat acute stroke in Japan s...

  What are Digital Health Technologies? Over the past few years, the healthcare industry and its market landscape have undergone a significant transformation due to the growth and development of Digital Health in the Field of Oncology , such as mobile health (mHealth) apps , electronic health records (EHRs), electronic medical records (EMRs), wearable devices, telehealth, and telemedicine, as well as personalized medicine. The main goals of digital health are to improve results, remove barriers to patient-clinician contact, and manage symptoms outside of the immediate region of therapy. The underlying components of digital health technologies are computing platforms, networking, software, and sensors. In a short amount of time, these technologies have been able to completely transform the way healthcare is provided. Digital health technologies are crucial for controlling acute and chronic diseases and for achieving the best possible health and wellbeing. Similar to how they could...

  Hemophilia A Treatment Landscape Despite historical ups and downs, hemophilia A patient treatment has significantly improved over the past 40 years. The modern advancement of hemophilia therapies began with the revolutionary discovery of cryoprecipitate in 1964. Several years later, scientists discovered that plasma-derived factors are focused on FVIII products. This category saw the approval of a number of hemophilia A drugs that were easier to administer than cryoprecipitate or fresh-frozen plasma, such as FEIBA (Pfizer), MONOCLATEP (CSL Behring), and HEMOFIL-M . The development of recombinant therapy in the 1980s changed the situation for those who have hemophilia A. There were only short half-life (SHL) recombinant medicines available prior to the approval of the first extended half-life (EHL) in the US (ELOCTATE; 2014). Other treatments avoid using the inhibitor-specific drugs utilized in hemophilia A. One of the most profitable bypass agents is Novonordisk's NOVOSEVEN ,...